> ## Content Index
> Fetch the complete content index at: https://biopharmabrief.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# What Happens When Your Watch Becomes a Medical Tool?
- URL: https://biopharmabrief.com/what-happens-when-your-watch-becomes-a-medical-tool/
- Published: 2026-10-07T14:00:33.000Z
- Updated: 2026-10-07T14:00:33.000Z
- Author: Logan Mavar

*Everyday wearables are gaining medical capabilities, opening new possibilities for early detection and care between appointments.*

The watch that delivers your text messages can now flag patterns suggesting high blood pressure. The band you wear to track workouts can record an electrocardiogram. FDA-cleared medical features are becoming part of devices people are already wearing.

That creates a different starting point for care. A potential problem can surface before someone notices symptoms or schedules an appointment. Clinicians can receive information collected beyond the brief window of an office visit.

Apple, Oura, WHOOP, Hilo and Empatica are pursuing different parts of that opportunity. Their progress is expanding where health information originates, how patients access it and what care teams can learn between appointments.

## **Apple is bringing medical alerts into everyday life**

Apple’s [hypertension notification feature](https://www.apple.com/newsroom/2025/09/new-versions-of-apples-software-platforms-are-available-today/?ref=biopharmabrief.com) received FDA clearance in September 2025\. It analyzes optical heart sensor data over 30-day periods for patterns suggesting hypertension in eligible adults aged 22 and older without a previous diagnosis.

A notification prompts users to take blood pressure measurements with a separate cuff for seven days and discuss the results with a healthcare professional. A watch someone already wears every day can now alert them to a potential health problem they might otherwise miss.

Clinical evidence is also developing. A [randomized trial announced by Amsterdam UMC in January 2026](https://www.amsterdamumc.org/en/research/institutes/amsterdam-cardiovascular-sciences/news/smartwatch-use-enhances-the-detection-of-heart-arrythmias-increasing-the-quality-of-care.?ref=biopharmabrief.com) found that Apple Watch screening increased atrial fibrillation detection over six months in patients at elevated stroke risk. More than half of those diagnosed in the smartwatch group had no symptoms, showing how wearables can uncover a heart rhythm disorder that might otherwise go unnoticed.

## **Oura and WHOOP are building a broader health relationship**

Oura and WHOOP are bringing more of a person’s health information into the platforms they already use.

Both offer Quest Diagnostics blood testing alongside wearable data. [Oura’s Health Panels](https://ouraring.com/blog/health-panels/?ref=biopharmabrief.com) generally measure 50 biomarkers, with results reviewed through its medical partner, SteadyMD. [WHOOP’s Advanced Labs](https://www.whoop.com/us/en/press-center/whoop-launches-specialized-panels-to-deliver-deeper-more-personalized-health-insights/?ref=biopharmabrief.com) includes comprehensive and specialized testing that measures over 75 biomarkers across panels. Both also offer ways for eligible users to bring medical records into their apps, including [WHOOP’s HealthEx integration](https://www.whoop.com/us/en/press-center/whoop-and-healthex-partner-to-connect-medical-records-and-biometric-data-to-deliver-more-personalized-health-insights/?ref=biopharmabrief.com).

WHOOP additionally offers an [FDA-cleared ECG feature](https://www.businesswire.com/news/home/20250508546933/en/WHOOP-Unveils-WHOOP-5.0-and-WHOOP-MG-Powerful-New-Devices-with-Breakthrough-Health-and-Longevity-Features?ref=biopharmabrief.com) that lets users take readings from their wrist and share them directly with a healthcare provider. Its Heart Screener detects signs of atrial fibrillation and provides irregular heart rhythm notifications. In August 2026, it made [Advanced Labs available without a WHOOP wearable](https://www.whoop.com/us/en/press-center/whoop-makes-advanced-labs-available-without-a-wearable-membership/?ref=biopharmabrief.com), extending its business beyond the band.

These platforms bring laboratory results and medical history together with everyday measurements of sleep, activity and recovery. For consumers, that creates a more accessible view of their health. For the companies, it expands their role from tracking fitness to organizing information that can inform conversations about care.

## **Hilo and Empatica target specific monitoring needs**

Other companies are building wearables around particular measurements and clinical tasks.

Hilo, developed by Aktiia, focuses on blood pressure. In July 2025, the FDA [cleared its G0 system](https://hilo.com/en-ca/blogs/pre/hilo-aktiia-g0-fda?ref=biopharmabrief.com) for over-the-counter spot measurements in eligible adults while stationary.

Its U.S. offering, [Hilo Core](https://www.prnewswire.com/news-releases/hilo-launches-the-worlds-first-blood-pressure-health-system-turning-snapshots-into-patterns-302829835.html?ref=biopharmabrief.com), is a general wellness system. It combines an upper-arm cuff, a wristband and an app that displays blood pressure patterns over time. In Europe, Hilo’s Bracelet G1 meets regulatory requirements for use as a medical device.

Empatica builds directly for clinical applications. Its prescription [EpiMonitor](https://www.empatica.com/blog/empatica-epimonitor-epilepsy-monitoring/?ref=biopharmabrief.com) detects patterns associated with generalized tonic-clonic seizures lasting at least 20 seconds in epilepsy patients aged six and older, triggering calls and texts to designated caregivers.

An [August 2026 FDA clearance](https://www.empatica.com/blog/empatica-receives-fda-clearance-for-parkinson-s-monitoring/?ref=biopharmabrief.com) expanded its platform into Parkinson’s monitoring, including quantification of tremor, slowness of movement and involuntary movement. For Hilo and Empatica, the wearable’s value comes from a defined monitoring task: tracking blood pressure, alerting a caregiver or measuring Parkinson’s symptoms.

## **Can wearables extend primary care?**

The opportunity arrives as U.S. primary care faces [continued underinvestment and workforce strain](https://www.milbank.org/2026/02/2026-primary-care-scorecard-shows-continued-underinvestment-workforce-strain/?ref=biopharmabrief.com). HRSA projects a [shortage of approximately 70,610 primary care physicians by 2038](https://bhw.hrsa.gov/data-research/projecting-health-workforce-supply-demand?ref=biopharmabrief.com).

Connected monitoring already provides a way to extend care beyond the office. Through [remote patient monitoring](https://www.cms.gov/medicare/coverage/telehealth/remote-patient-monitoring?ref=biopharmabrief.com), medical devices automatically transmit measurements such as blood pressure and glucose to providers for review and management.

Consumer wearables create another opportunity to expand that reach. A [2026 AMA–Medscape survey](https://www.ama-assn.org/press-center/ama-press-releases/wearable-data-adoption-stalled-system-barriers?ref=biopharmabrief.com) found that full integration of wearable data into clinical workflows remained at 6% or less across the six countries surveyed, leaving substantial room to connect these devices with care teams.

Wearables could help care teams recognize when a patient needs attention between visits, prompting a call, further testing or an appointment. Earlier detection can also create demand for a primary care system already under strain. More information alone does not expand clinical capacity. Turning those signals into care requires staff to review them, prioritize patients and arrange follow-up. For patients, a health problem could become the reason for an appointment, rather than a discovery made during one.